181 related articles for article (PubMed ID: 37552307)
21. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
Yearley JH; Gibson C; Yu N; Moon C; Murphy E; Juco J; Lunceford J; Cheng J; Chow LQM; Seiwert TY; Handa M; Tomassini JE; McClanahan T
Clin Cancer Res; 2017 Jun; 23(12):3158-3167. PubMed ID: 28619999
[No Abstract] [Full Text] [Related]
22. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis.
Zhang S; Zheng M; Nie D; Xu L; Tian H; Wang M; Liu W; Feng Z; Han F
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253001
[TBL] [Abstract][Full Text] [Related]
24. Biomarkers for immunotherapy response in head and neck cancer.
Gavrielatou N; Doumas S; Economopoulou P; Foukas PG; Psyrri A
Cancer Treat Rev; 2020 Mar; 84():101977. PubMed ID: 32018128
[TBL] [Abstract][Full Text] [Related]
25. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
[TBL] [Abstract][Full Text] [Related]
26. The effects of PD-1/PD-L1 checkpoint inhibitors on recurrent/metastatic head and neck squamous cell carcinoma: a critical review of the literature and meta-analysis.
Clarke E; Eriksen JG; Barrett S
Acta Oncol; 2021 Nov; 60(11):1534-1542. PubMed ID: 34410881
[TBL] [Abstract][Full Text] [Related]
27. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D;
Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945
[TBL] [Abstract][Full Text] [Related]
28. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
[TBL] [Abstract][Full Text] [Related]
29. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
30. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy.
Chen Y; Ding X; Bai X; Zhou Z; Liu Y; Zhang X; Yu J; Hu M
Int Immunopharmacol; 2023 Jul; 120():110329. PubMed ID: 37207445
[TBL] [Abstract][Full Text] [Related]
31. Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma.
Desilets A; Soulières D
Expert Opin Drug Saf; 2020 Aug; 19(8):927-934. PubMed ID: 32458764
[TBL] [Abstract][Full Text] [Related]
32. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
[TBL] [Abstract][Full Text] [Related]
33. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
[TBL] [Abstract][Full Text] [Related]
34. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
[TBL] [Abstract][Full Text] [Related]
35. Constructing heterogeneous single-cell landscape and identifying microenvironment molecular characteristics of primary and lymphatic metastatic head and neck squamous cell carcinoma.
Zhang J; Liu Y; Xia L; Zhen J; Gao J; Atsushi T
Comput Biol Med; 2023 Oct; 165():107459. PubMed ID: 37713790
[TBL] [Abstract][Full Text] [Related]
36. PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.
Müller T; Braun M; Dietrich D; Aktekin S; Höft S; Kristiansen G; Göke F; Schröck A; Brägelmann J; Held SAE; Bootz F; Brossart P
Oncotarget; 2017 Aug; 8(32):52889-52900. PubMed ID: 28881780
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.
Evrard D; Hourseau M; Couvelard A; Paradis V; Gauthier H; Raymond E; Halimi C; Barry B; Faivre S
Oncoimmunology; 2020 Nov; 9(1):1844403. PubMed ID: 33299655
[TBL] [Abstract][Full Text] [Related]
38. Determining PD-L1 expression in head and neck squamous cell carcinoma using immunohistochemistry.
Mishra PS; Sidhu A; Dwivedi G; Mulajker DS; Awasthi S
Indian J Cancer; 2022; 59(4):474-479. PubMed ID: 33753620
[TBL] [Abstract][Full Text] [Related]
39. Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit.
Tomlins SA; Khazanov NA; Bulen BJ; Hovelson DH; Shreve MJ; Lamb LE; Matrana MR; Burkard ME; Yang ES; Edenfield WJ; Dees EC; Onitilo AA; Thompson M; Buchschacher GL; Miller AM; Menter A; Parsons B; Wassenaar T; Hwang LC; Suga JM; Siegel R; Irvin W; Nair S; Slim JN; Misleh J; Khatri J; Masters G; Thomas S; Safa M; Anderson DM; Kwiatkowski K; Mitchell K; Hu-Seliger T; Drewery S; Fischer A; Plouffe K; Czuprenski E; Hipp J; Reeder T; Vakil H; Johnson DB; Rhodes DR
Commun Med (Lond); 2023 Feb; 3(1):14. PubMed ID: 36750617
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
